Project Grant R43GM165212
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $350K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02134, USA
Similar Awards
- The National Institutes of Health Office of the Director awarded the Trustees of Boston University $1,144,500 on September 4, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to develop nanobody-based probes that enable precise, multiplexed, and genetically-encoded perturbations to protein conformations and states in human cells. The work will generate a novel class of probes to realize large-scale, unbiased protein interaction mapping through pooled screening methodologies,...
- The National Institutes of Health Office of the Director awarded Dana-Farber Cancer Institute, Inc. $845,500 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to design de novo allosteric proteins that sense and respond to small molecules. The research aims to develop "active" proteins that undergo conformational changes upon ligand binding, enabling programmable control of signaling at the nanoscale. The work combines computational design and...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services, awarded Trustees of Boston University $449,625 on March 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to advance targeted delivery of intracellular protein therapeutics using virus-like particles derived from retroviruses. The research focuses on developing design principles for next-generation virus-like particles (VLPs) that enhance cell-specific...
- The National Institute of Biomedical Imaging and Bioengineering awarded Trustees of Boston University $641,300 on May 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286, assistance type Project Grant) to develop next-generation chemoproteomic affinity-based peptide probes (CAFBPs) for targeted profiling of oncogenic kinase activity in circulating tumor cells. The project addresses technical barriers in isolating and...
- The National Institute of General Medical Sciences awarded The Broad Institute, Inc. $464,032 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop computational methods for mapping intercellular circuits governing complex tissues, specifically mucosal epithelia in the intestine, airway, nose, urogenital tract, and related barrier surfaces. The project addresses two key analytical challenges: uncovering intercellular regulatory signals that...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded Brigham & Women's Hospital Inc. $230,388 on March 12, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop small molecule inhibitors of the E3 ligase NEDD4. The project consists of two research aims. Aim 1 investigates the structural dynamics of the NEDD4 HECT domain through NMR spectroscopy, using different...
- The National Institute of General Medical Sciences awarded $1.243 million to Trustees of Tufts College on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop intracellular delivery approaches that overcome the hook effect in proteolysis-targeting chimera (PROTAC) technology and improve protein degradation efficiency. The project addresses a technical limitation in PROTAC-mediated protein degradation where elevated PROTAC concentrations saturate...
- The National Institute of General Medical Sciences awarded Boston College $641,700 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop chemical-proteomic tools for investigating cysteine modifications in proteins. Boston College will expand chemoproteomic platforms to investigate protein regulation through metal binding, oxidation, and covalent liganding of cysteines localized in different subcellular compartments. The research encompasses...
- The National Institute of General Medical Sciences awarded the Trustees of Boston University $433,750 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop network-based computational models for understanding continuous cell states in human development and disease. Over five years through February 28, 2031, the research group will create methods to integrate multiple modalities of large-scale genomics data, with emphasis on epigenetics and the...
- The National Institute of General Medical Sciences awarded Imagen Bioworks Inc. $349,243 on September 12, 2025, under the Biomedical Research and Research Training program (CFDA 93.859) to develop SPOTLIGHT-OMICS, a scalable spatiotemporal-omics platform for pre-clinical drug discovery. The platform isolates disease-relevant cell subpopulations showing altered spatiotemporal phenotypes after drug exposure and subjects isolated cells to subsequent omics assays, linking cellular spatiotemporal...